Premium
Candidate's Thesis: Platelet‐Activating Factor–Induced Hearing Loss: Mediated by Nitric Oxide?
Author(s) -
Rhee ChungKu
Publication year - 2003
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-200312000-00001
Subject(s) - platelet activating factor , nitric oxide , antagonist , nitric oxide synthase , cochlea , guinea pig , chemistry , medicine , endocrinology , pharmacology , receptor , anatomy
Objectives/Hypothesis Platelet‐activating factor (PAF)in middle ear effusion is thought to induce hearing loss. The purpose of this study is to investigate the role of nitric oxide (NO) in the mechanism of PAF‐induced hearing loss by studying the effects of PAF application on the round window membrane (RWM) with and without PAF‐antagonist NO‐blocker. Study Design Longitudinal study on randomized guinea pigs using PAF to induce hearing loss. Methods Guinea pigs were divided into four groups: PBS, PAF, PAF‐antagonist, and L‐NAME. The PBS group received phosphate buffered saline (PBS) and the PAF groups received 10, 20, and 40 μg of PAF soaked into gelfoam and placed on the RWM. PAF‐antagonist (WEB 2170) and NOS inhibitor NG‐nitro‐l‐arginine‐methylester (L‐NAME) were injected intraperitoneally prior to PAF 20 μg application on the RWM. The following three tests were performed on each animal group: Hearing was tested with an auditory brainstem response (ABR) test over 24 hours. At the end of 24 hours, cochlear hair cells were examined by scanning electron microscopy (SEM) and immunohistochemistry was carried out on the cochlea to test the expression of inducible nitric oxide synthase (iNOS). Results The PAF group developed significant elevation of ABR threshold and cochlear hair cell damage in the SEM group as compared with the PBS control group. The PAF‐antagonist (WEB 2170) and the L‐NAME groups did not show significant elevation of ABR threshold and cochlear hair cell damage compared with the group administered PAF 20 μg, but in the PAF‐antagonist group, the elevation of ABR threshold was significant compared with that of the PBS control group, whereas it was not significant compared with the PBS group in the L‐NAME group. Strong expression of iNOS on cochlea was observed in the PAF group and lighter expression was seen in PBS, WEB 2170, and L‐NAME groups. Conclusions This study demonstrated that PAF placed on the RWM induced hearing loss and cochlear hair cell damage. The PAF‐antagonists and L‐NAME prevented the PAF‐induced hearing loss and inhibited iNOS expression in the cochlea. These findings suggest that the PAF‐induced hearing loss caused by cochlear hair cell damage may have been mediated by NO. PAF‐antagonists and L‐NAME may have future therapeutic implications in preventing sensorineural hearing loss associated with chronic otitis media. The results of this study have significant potential clinical application.